Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — FY2025 Earnings Presentation
37 slides from Ekf Diagnostics's earnings presentation, March 2026
Slide 1: EKF Diagnostics Holdings plc Preliminary Results Presentation
EKF Diagnostics Holdings plc Preliminary Results Presentation Year Ended 31 December 2025 ekfdiagnostics.com
Slide 2: The EKF Team
The EKF Team Julian Baines MBE Gavin Jones Stephen Young Executive Chair Chief Executive Officer Chief Financial Officer Experienced CEO and Exec Chair Previously Chief Product Officer for Experienced Finance Director & CFO with proven industry acumen EKF Diagnostics Holdings plc AIM experience acro
Slide 3: Five-Year Strategy: Sustainable Growth
Five-Year Strategy: Sustainable Growth Target 2029 Target 2029 Target 2029 #1 Point-of-Care (POC) #1 Ketone Testing (β-HB) Transform EKF Life Hemoglobin Laboratory & POC Sciences into a CDMO • Fully develop the US • Continue to develop β-HB • Refocus the strategy to blood bank business Liquicolor wi
Slide 4: 2025: Setting the Foundation of the Strategy
2025: Setting the Foundation of the Strategy Strategic Execution Operational Focus Financial Performance • Five-year strategy launched, • Completed simplification of • Grew revenue by 3% to communicated and product portfolio £51.6m whilst implementing implemented strategy • Finalized Hematology • In
Slide 5: Board Expectations 2025
Board Expectations 2025: Capital deployment to deliver Implement share buyback to improve 01 sustainable growth and unlock 02 earnings per share (EPS) unrealized potential Investment in Operational Excellence to increase production Utilize cash reserves to implement a progressive, ongoing capacity,
Slide 6: #1 Point-of-Care (POC) Hemoglobin
#1 Point-of-Care (POC) Hemoglobin Objectives achieved • Grew the LATAM the Hematology business by 57% versus 2024, driven heavily by the improvement in Peru and buoyed by new business in Brazil • Greater focus on the US Hemoglobin market where the dedicated Pont-of-Care commercial team has delivered
Slide 7: Hematology Analyzers Sold
Hematology Analyzers Sold Hemo Control DiaSpect HemataSTAT Hemo Control 5.7k Strong push on Hemo Control analyzers in 2025 with a 53% increase in the number of devices sold vs 2024, high volumes in LATAM and East Africa DiaSpect 10.2k DiaSpect analyzer placement has been encouragingly 16 thousand hi
Slide 8: Hematology Tests Sold
Hematology Tests Sold Hemo Control DiaSpect HemataSTAT & Ultracrit Hemo Control 18.7m Again, Hemo Control was the star here with a 11% increase in the number of tests sold, this likely could’ve been higher if we had greater capacity in production DiaSpect 58 million 40.6m The number of cuvette sales
Slide 9: Point-of-Care Outside Strategic Focus
Point-of-Care Outside Strategic Focus Point-of-Care Revenue £7,000 Quo-Test and Quo-Lab 7% HbA1c POC shows an average 7% growth versus £6,000 2024, mainly from Quo-Lab which has proven robust in £5,000 a challenging marketplace £4,000 Biosen £’m £3,000 14% Biosen has shown 14% growth versus 2024 att
Slide 10: #1 Ketone Testing (β-HB) Laboratory & POC
#1 Ketone Testing (β-HB) Laboratory & POC Objectives achieved • Achieved 12% growth in our top 3 β-HB Liquicolor distributors in the US, whilst growing the overall β-HB business by over 10% • Significant progress made on the product improvement project focused on building on our existing significant
Slide 11: β-HB Focus
β-HB Focus SSWB BHB Top 3 Customers £6,000 18% £5,000 2% £4,000 £’000 £3,000 £14.2 million £2,000 29% £1,000 £- A B C 2024 2025 Growth across the portfolio Distributor strength 10% Excellent growth across both β-HB Liquicolor at 10% 12% Top 3 distributors showing positive growth at 12% and Stat-Site
Slide 12: Transform EKF Life Sciences into a CDMO
Transform EKF Life Sciences into a CDMO Objectives achieved • Strategy realigned to match requirements of Pharma and Biotech businesses based upon pipeline opportunities and capabilities at our Life Sciences facility • Brought in significant new diagnostic enzyme contract with high value product pip
Slide 13: Life Sciences Update
Life Sciences Update Revenue 3,000 Fermentation lower 2,500 (3%) Whilst there has been good progress in fermentation, we have seen a drop in 2025 due to some projects not 2,000 continuing with others not fully kicking in until 2026 Contract Manufacturing grows £’000 1,500 £1.5m We have seen a positi
Slide 14: Objectives 2026
Objectives 2026: Commercial development in the Focus on Operational Excellence with 01 strategically important markets and 02 a strong CapEx plan to support future product areas success • Expanded distributor engagement events in key strategic • Continued development and implementation of new market
Slide 15: Building on the Foundation 2026
Building on the Foundation 2026 After a transformational year, focus will be on delivery in the strategically important Point-of-Care Hematology market Ensuring full installation and utilization of Point-of-Care Hematology analyzers to drive high-margin consumable sales, in addition to capitalizin
Slide 16: Financial
Financial 16
Slide 17: Financial Highlights
Financial Highlights • Revenues of £51.6m (2024: £50.2m) • Gross profit before exceptionals of £26.5m (2024: £24.4m) • Gross margin improved to 51% (2024: 48%) • Adjusted EBITDA of £12.4m (2024: £11.3m) • Profit before tax of £7.1m (2024: £6.3m) • Cash generated from operations of £11.6m (2024: £12.
Slide 18: Business Units
Business Units £ millions 2025 2024 +/- £k Point-of-Care 33,012 31,404 1,608 Life Sciences 17,887 16,655 1,232 Other 457 989 (532) 02 Discontinued Products 208 1,146 (938) Total Group Revenues 51,564 50,194 1,370 03 18
Slide 19: Income Statement
Income Statement £ '000 2024 2023 +/- £k Revenue 51,564 50,194 1,370 Cost of Sales (25,084) (25,798) 714 Exceptional items - (330) 330 Gross Profit 26,480 24,066 2,414 Gross Margin % 51% 48% 3% 02 Admin Expenses/Overheads (19,734) (18,078) (1,656) Exceptional items - (22) 22 Other Income 232 294 (62
Slide 20: Thank You
Thank You Thank You ekfdiagnostics.com
Slide 21: Appendices
Appendices 21
Slide 22: Non-executive Directors
Non-executive Directors Christian Rigg - Senior Independent Non-executive Director Chris Rigg is a chartered accountant who has significant executive experience at both public and private companies. He is Chief Executive Officer of PAM Group, a private equity backed healthcare business. He was forme
Slide 23: ESG - 2025
ESG - 2025 EKF continued to strengthen its ESG maturity in 2025, delivering progress across environmental, social, and governance priorities. The outcomes reflect the organization’s broader commitment to responsible growth, operational sustainability, and long-term value creation. 23
Slide 24: Environment - 2025
Environment - 2025 • CO₂ emissions – 11.5% reduction in electricity-related emissions • Sustainable packaging - improvements were implemented, across the group including the use of FSC-certified materials for key product lines • Sustainable mobility initiatives - expanded access to • Energy audits -
Slide 25: Social - 2025
Social - 2025 • Proactive health-and-wellbeing initiatives - regular health • Customer engagement - advanced through the launch of the first activities and vaccination programmes as well as an Employee digital customer-satisfaction survey, supporting more consistent Assistance Program (EAP) for ment
Slide 26: Governance - 2025
Governance - 2025 • Over 30% women in management - met the target, • ESG governance structures - continued to mature through the strengthening leadership diversity Global ESG Working Group and ESG Committee, ensuring • NIS-2 cybersecurity requirements - work began on implementing oversight, alignmen
Slide 27: Balance Sheet – Assets
Balance Sheet – Assets £ '000 2025 2024 +/- £k Fixed assets 22,299 24,034 (1,735) Intangible assets 27,884 28,922 (1,038) Investments 54 228 (174) Deferred tax 25 9 16 Inventories 8,302 7,393 909 02 Receivables 6,739 6,803 (64) Corporation tax - 55 (55) Cash 15,834 14,301 1,533 03 Total assets 81,13
Slide 28: Balance Sheet – Liabilities
Balance Sheet – Liabilities £ '000 2025 2024 +/- £k Payables 6,719 6,717 2 Deferred tax liabilities 2,455 1,198 1,257 Corporation tax 1,688 618 1,070 Borrowings - - - 02 Total creditors 10,862 8,533 2,329 Capital and reserves 69,050 72,327 (3,277) Minority interest 1,225 885 340 03 Total equity 70,2
Slide 29: Cash Flow
Cash Flow £ '000 2025 2024 +/- £k Net cash generated from 9,707 13,656 (3,949) operating activities Net cash (used in)/generated by (2,338) (2,662) 324 investing activities Net cash used in financing (5,863) (4,077) (1,786) activities Net (decrease)/increase in cash 1,506 6,917 (5,411) 02 and cash e
Slide 30: EKF at a glance
EKF at a glance 30
Slide 31: Point-of-Care and Life Sciences
Point-of-Care Life Sciences Providing quick and accurate results for Cutting-edge technology with capacity to healthcare professionals to make rapid deliver projects from research to decisions at or near the patient’s location commercial scale production Hematology Precision Fermentation Blood donat
Slide 32: Global Presence
Global Presence Distribution to over 120 countries Germany EKF has two ISO 13485 certified sites in Germany, located in Magdeburg and Leipzig, manufacturing and distributing our Point-of-Care portfolio Texas Our FDA regulated facility in Boerne, Texas manufactures our class-leading β-HB chemistry re
Slide 33: Point-of-care: Hematology Featured Products
Point-of-care: Featured Products Delivering immediate lab-quality results in just one second, DiaSpect Tm Hematology streamlines blood analysis, making it a valuable tool for healthcare screening and testing, DiaSpect Tm is essential for professionals in remote or mobile settings. Hemo Control is a
Slide 34: Point-of-care: Diabetes Featured Products
Point-of-care: Featured Products The easy-to-use Biosen C-Line is a familiar name in laboratories, sports medicine, Diabetes and diabetes clinics, with two models available, the Biosen C-Line Clinic (up to 20 samples) and Biosen C-Line GP+ (up to 5 samples). Providing lab-accurate results in just fo
Slide 35: Point-of-care: Specialist Featured Products
Point-of-care: Featured Products Lactate Scout Sport is a reliable lactate analyzer perfect for training outdoors, in Specialist the gym, or for analysing performance in a sports lab, Lactate Scout Sport is the number one choice for sports scientists and professional athletes. Lactate Scout Vet is a
Slide 36: Life Sciences: Portfolio Featured Products
Life Sciences: Featured Products The Beta-Hydroxybutyrate LiquiColor® reagent is a quantitative, FDA-cleared test Portfolio for detecting ketones and monitoring diabetic ketoacidosis, compatible with open- channel analyzers, it integrates seamlessly into laboratory workflows. Precision Fermentation
Slide 37: Disclaimer
Disclaimer The information contained in these slides and the accompanying oral presentation (together, the “Presentation”) has been prepared by EKF Diagnostics Holdings plc (the “Company”). The Presentation is subject to updating, completion, revision, and amendment without notice, and as such, it m
EKF Diagnostics Holdings — FY2025 Earnings Presentation on 6ix